
Clinical Associate Professor of Internal Medicine
Medical School
1150 W. Medical Center Drive MSRBIII
Ann Arbor
Michigan, 48109 United States
[email protected]
Ann Arbor
Michigan, 48109 United States
Available to mentor
Justin Oldham

Clinical Associate Professor
-
FellowshipUniversity of Chicago, Chicago, 2016
-
ResidencyUniversity of California at Davis, USA, 2009
-
M.S.University of Chicago, 2016
-
M.D.University of Colorado, 2006
-
B.A.University of Colorado, 2002
-
PhDUniversity of Michigan Medical School
-
Center MemberPrecision Health Initiative
-
Moen EV, Prior TS, Kreuter M, Wuyts WA, Molina-Molina M, Wijsenbeek M, Morais A, Tzouvelekis A, Ryerson CJ, Caro F, Buendia-Roldan I, Magnusson JM, Lee JS, Morisett J, Oldham JM, Troy LK, Funke-Chambour M, Alberti ML, Borie R, Walsh SLF, Rajan S, Kondoh Y, Khor YH, Bendstrup E. BMC Pulmonary Medicine, 2025 Dec 1; 25 (1):Journal ArticleDiagnosis, screening, and follow-up of patients with familial interstitial lung disease: Results from an international survey
DOI:10.1186/s12890-025-03532-0 PMID: 39901224 -
Alqalyoobi S, Smith JA, Maddali MV, Pugashetti JV, Newton CA, Kim JS, Linderholm AL, Chen C-H, Ma S-F, Bose S, Murray S, Adegunsoye A, Strek ME, Garcia CK, Wolters PJ, Martinez FJ, Noth I, Oldham JM. Am J Respir Crit Care Med, 2025 Apr 10;Journal ArticleProteomic Biomarkers of Survival in Non-IPF Interstitial Lung Disease.
DOI:10.1164/rccm.202407-1506OC PMID: 40208180 -
Wang JM, Bose S, Murray S, Labaki WW, Kazerooni EA, Chung JH, Flaherty KR, Han MK, Hatt CR, Oldham JM. Ann Am Thorac Soc, 2025 Apr 10;Journal ArticleQuantitative CT Measures of Lung Fibrosis and Outcomes in the National Lung Screening Trial.
DOI:10.1513/AnnalsATS.202410-1048OC PMID: 40208581 -
Carter H, Costa RM, Adams TS, Gilchrist TM, Emch CE, Bame M, Oldham JM, Huang SK, Linderholm AL, Noth I, Kaminski N, Moore BB, Gurczynski SJ. JCI Insight, 2025 Mar 24; 10 (6):Journal ArticleCD103<sup>+</sup> dendritic cell–fibroblast crosstalk via TLR9, TDO2, and AHR signaling drives lung fibrogenesis
DOI:10.1172/jci.insight.177072 PMID: 39964756 -
Koschel D, Richeldi L, Assassi S, Azuma A, Cottin V, Hoffmann-Vold A, Kreuter M, Liu Y, Maher T, Oldham J, Stowasser S, Valenzuela C, Wijsenbeek M, Zoz D, Martinez F. Pneumologie, 2025 Mar 19; 79 (S 01): s32 - s33.Journal ArticleBaseline characteristics of patients enrolled in FIBRONEER(TM)-IPF, a Phase III randomised placebo-controlled trial of the preferential PDE4B inhibitor BI 1015550 in patients with idiopathic pulmonary fibrosis
DOI:10.1055/s-0045-1804605 -
Bonella F, Maher T, Assassi S, Azuma A, Cottin V, Hoffmann-Vold A, Kreuter M, Oldham J, Richeldi L, Valenzuela C, Wijsenbeek M, Coeck C, Schlosser A, Wachtlin D, Martinez F. Pneumologie, 2025 Mar 19; 79 (S 01): s33 - s34.Journal ArticleBaseline characteristics of patients enrolled in the FIBRONEER-ILD trial of nerandomilast (BI 1015550)
DOI:10.1055/s-0045-1804606 -
Oldham JM, Neely ML, Wojdyla DM, Gulati M, Li P, Patel DC, Palmer SM, Todd JL, Idiopathic Pulmonary Fibrosis-Prospective Outcomes Registry Investigators . Chest, 2025 Feb 26;Journal ArticleChanges in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis.
DOI:10.1016/j.chest.2025.02.018 PMID: 40020995 -
Chin D, Hernandez-Beeftink T, Donoghue L, Guillen-Uio B, Leavy OC, Adegunsoye A, Booth HL, CleanUP-IPF Investigators of the Pulmonary Trials Cooperative , Fahy WA, Fingerlin TE, Gooptu B, Hall IP, Hart SP, Hill MR, Hirani N, Hubbard RB, Johnson S, Kaminski N, Lorenzo-Salazar JM, Ma S-F, McAnulty RJ, McCarthy M, Stockwell AD, Maher TM, Millar AB, Molyneaux PL, Molina-Molina M, Navaratnam V, Neighbors M, Oldham JM, Parfrey H, Saini G, Sayers I, Rebecca Sheng X, Stewart ID, Strek ME, Tobin MD, Whyte MK, Zarcone MC, Zhang Y, Martinez F, Yaspan BL, Reynolds CJ, Schwartz DA, Flores C, Noth I, Gisli Jenkins R, Allen RJ, Wain LV. 2025 Feb 2;PreprintGenome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets.
DOI:10.1101/2025.01.30.25321017 PMID: 39974050